Posts tagged EBITDA
RBC upgrades CRH Medical to OP

RBC Capital Markets upgraded CRH Medical (TSX:CRH; NYSE MKT:CRHM) to “outperform” from “sector perform” but lowered its price target to $6 (Canadian) from $8.50. The stock closed at $4.07 on July 20.

Read More
Roth downgrades ANI Pharma to neutral

Roth Capital Partners downgraded ANI Pharmaceuticals (NASDAQ:ANIP) to “neutral” from “buy,” pending the company’s 2017 financial guidance. Roth maintained its $69 price target for the stock, which was quoted at $59.53, down $3.52, in the afternoon session on Feb. 22.

Read More
Cardiovascular Systems, Kindred on Feltl Top Idea list

Feltl’s Top Ideas list for 2017 includes Cardiovascular Systems (NASDAQ:CSII) and Kindred Biosciences (NASDAQ:KIN).

Read More
Canaccord ups AtriCure price target to $23

Canaccord Genuity raised its price target for AtriCure (NASDAQ:ATRC) to $23 from $21 after the company reported third quarter results. The stock is trading at $17.74, up $2.54, at midday on Friday.

The third quarter represented “sentiment-changing results for an under-appreciated, under-valued, high margin med-tech growth story,” writes analyst Jason Mills. “Bottom line: buy this stock,” he added.

Read More
Stifel starts Tabula Rasa HealthCare at buy

Stifel launched coverage of Tabula Rasa HealthCare (NASDAQ:TRHC) with a “buy” rating and $17 price target. The stock closed at $14.23 on Friday.

Tabula is a healthcare information technology company focused on medication management solutions created from equal parts data and science, and aimed, when appropriate, at the individual using genetic information.

Read More
Cormark starts BioSyent at buy

Cormark Securities initiated coverage on BioSyent (TSX-V: RX) with a “buy” recommendation and $10.25 target price. The stock closed at $8.40 on Thursday.

BioSyent establishes and builds out pharmaceutical brands in the Canadian market as well as a growing interest in international jurisdictions. Currently targeting niche products with annual peak revenues of about $20-million each, BioSyent has amassed a portfolio of 11 assets, all of which are growth-stage products or earlier.

Read More
Roth starts Recro Pharma at buy

Roth Capital Partners has launched coverage of Recro Pharma (NASDAQ:REPH) with a “buy” rating and a $24 price target. The stock closed at $9.31 on Thursday.

“The impetus for our buy rating on Recro shares is the upside potential of the pain management pipeline combined with the downside protection from the manufacturing business,” writes analyst Scott Henry.

Read More
Leerink starts Endologix at market perform

Leerink Partners initiated coverage of Endologix (NASDAQ:ELGX) with a “market perform” rating and $13 price target. The stock closed at $12.22 on Friday.

Endologix is the largest abdominal aortic aneurysm (AAA) pure play and holds the No. 4 position in the $1.5-billion worldwide AAA market.

Read More
Leerink starts American Renal at outperform

Leerink Partners has launched coverage of American Renal Associates (NYSE:ARA) with an “outperform” rating and $33 price target. The stock closed at $27.71 on Friday.

“Our positive thesis contemplates a forward adjusted EBITDA (excluding non-controlling interest) growth rate of 13% (2015-2019 estimated CAGR) and is based on three growth pillars,” writes analyst Ana Gupte.

Read More
Nobilis Health Q1 revenue climbs 35%

First quarter revenue for Nobilis Health (NYSE MKT:HLTH; TSX:NHC) rose 35% to a record $51.3-million, driven by increased case flow and a higher average revenue per case.

In the first quarter, we invested heavily in new technology and infrastructure to support our forecasted growth in 2016,” CEO, Harry Fleming, said in a statement.

Read More
Roth reinitiates coverage of NeoGenomics at buy

Roth Capital Partners has reinitiated coverage on NeoGenomics with a “buy” rating and target price of $10, following its acquisition of Clarient from GE Healthcare. The stock closed at $8.34 on Tuesday.

“We believe NeoGenomics is on the brink of demonstrating significant sales growth and operating leverage over the next several years as the two companies become fully integrated and realize likely better-than-anticipated revenue and cost synergies,” writes analyst Chris Lewis.

Read More
Roth starts Foundation Healthcare at buy

Roth Capital Partners has initiated coverage of Foundation Healthcare (OTC:FDNH) with a “buy” rating and $6 price target. The stock closed at $3.05 on Monday.

“The impetus for our buy rating is the potential of the company’s acquisition of University General Hospital (UGH) in Houston to drive increased EBITDA and EPS,” writes analyst Scott Henry, adding that progress should start to be apparent with first quarter results this year to be reported in May.

Read More